ATH (ATH) News
Follow ATH (ATH) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 9 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Union Pacific upgraded to Buy by UBS for 2027 outlook
UBS upgraded Union Pacific to Buy, citing an expected 3.5% volume growth in 2027, including 6% to 7% intermodal volume growth, plus indications of a pricing tailwind from trucking into next year.
EQUITY | Sep 16, 2026, 04:01 PM UTC
M
Athabasca Oil downgraded at BMO on premium valuation risk
BMO analyst Tariq Saad downgraded Athabasca Oil’s rating to market perform from market outperform, citing that the shares are within the 10% threshold of the target.
ENERGY | Sep 16, 2026, 03:00 PM UTC
L
Alterity Therapeutics Price Target Announced at $10.00/Share by Lake Street
Ratings actions from Benzinga
NEWS | Sep 15, 2026, 04:06 PM UTC
L
RBC Capital maintains Athabasca Oil at Sector Perform, price target C$12
RBC Capital maintained its Sector Perform rating on Athabasca Oil Corp. The firm also maintained its C$12.00 per share price target, as reported by Baystreet/TradingView News.
EQUITY | Sep 10, 2026, 03:37 PM UTC
L
ATH: Disciplined growth, robust free cash flow, and fully funded expansions drive long-term value
Focused on high-quality thermal oil and Duvernay assets, the company targets strong per-share growth, robust free cash flow, and fully funded expansions. With an 85-year reserve life, disciplined capital returns, and a p
ENERGY | Sep 08, 2026, 08:19 PM UTC
L
Alterity Therapeutics to join Cantor Global Healthcare conference fireside chat
Alterity Therapeutics said David Stamler will participate in a fireside chat at the Cantor Global Healthcare Conference 2026.
EQUITY | Sep 03, 2026, 11:08 AM UTC
M
Burry warns of private credit shell game involving insurers
Michael Burry says a new academic paper exposes a private credit and private equity “shell game” that could shift losses onto taxpayers through life insurers.
EQUITY | Sep 03, 2026, 07:47 AM UTC
M
ATH net loss up 93% to A$23.4M; Phase 3 ATH434 on track
ATH reported net loss increased 93% to A$23.4M as R&D and admin costs rose, while its Phase 3 ATH434 trial is on track.
EQUITY | Aug 28, 2026, 07:02 AM UTC
L
Athene Holding Ltd. Declares Q3 Preferred Stock Dividends
Athene declares third quarter preferred stock dividends
EQUITY | Aug 03, 2026, 08:30 PM UTC